Nuclear Cardiology

Single photon computed tomography (SPECT) and positron emission tomography (PET) molecular imaging are used as primary cardiac imaging modalities to evaluate the function of the heart. It uses radioactive isotopes attached to sugars that are metabolized by cardiomyocytes. This creates an image of the metabolic activity of the heart and shows areas of ischemia or infarct. Other radiotracers can image the heart to diagnosis cardiac amyloidosis and sarcoidosis.

Bracco updates HeartSee coronary flow capacity software with new diagnostic features
Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor
The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD
Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.
Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging
After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.
U.S. moves closer to establishing domestic supply of Mo-99 for nuclear imaging
Society of Nuclear Medicine and Molecular Imaging President, Cathy Cutler, explains the long road to jump-starting a new U.S. domestic supply of imaging isotopes.

Combining AI with cardiac imaging helps predict heart attacks, cardiovascular deaths

The findings were presented virtually during the Society of Nuclear Medicine and Molecular Imaging's 2021 Annual Meeting.

Imaging advocates offer guidance after reported spate of SPECT/CT payment denials

The Society of Nuclear Medicine & Molecular Imaging said it’s received “many complaints” from the field pertaining to various commercial payers.

M&A mergers and acquisitions business deal

Medical imaging isotope producer Shine finalizes merger with fusion technology specialist

With the help of Phoenix's advanced industrial imaging capabilities, the new entity hopes to ramp up its production of molybdenum-99.

CCTA is a safe, effective alternative to SPECT in patients with stable chest pain

The findings come by way of the RESCUE Trial, which included more than 1,000 participants from 44 different sites.

Imaging experts slam Humana for ‘ill-informed and wrong’ decision to deny coverage for PET/CT exams

The pair said that without hearing a solid argument, they will be "relentless" in opposing the insurance giant's coverage determination.

Top nuclear imaging group ‘strongly disagrees’ with Humana’s decision to refuse coverage for PET/CT

The Society of Nuclear Medicine and Molecular Imaging said the move denies patients access to potentially lifesaving technologies.

Attralus completes financing to validate pan-amyloid nuclear imaging agent

Biopharmaceutical firm Attralus has completed a $25 million Series A financing designed to further validate its AT-01 pan-amyloid radiotracer for PET/CT.

SNMMI 2020: Imaging highlights connection between heart and kidneys in heart attack response

Researchers monitored how the heart and kidneys responded one day, three days, seven days and six weeks following an induced myocardial infarction.

Around the web

Cardiovascular Business

GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business

Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business

Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.